Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at HC Wainwright from $6.00 to $6.60. They now have a "buy" rating on the stock.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $3.00 price target on the stock.
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]